Equillium, Inc. - 8-K Filing
Equillium completes $20 million milestone closing of private placement following first patient dosing in EQ504 Phase 1 trial (Items: 3.02 Unregistered Sales of Equity Securities, 8.01 of this Current Report on Form 8-K is incorporated by reference under this Item 3, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)